Recent Advances in Modulating Mitophagy with Novel Drugs/Compounds
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 5 February 2025 | Viewed by 67
Special Issue Editor
Interests: innate immunity; molecular and cell biology; stem cell technology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Heart disease is a major threat to human health. Every day, 2396 people die from cardiovascular disease, according to 2019 data (obtained from The American Heart Association). Mitochondria are the most important organelles that provide cellular energy by liberating chemical energy via oxidative phosphorylation and then converting this energy in the form of ATP. The heart is beating all the time, and the demand for energy is very high, so mitochondrial damage can cause serious heart disease. Mitochondria are in a dynamic balance of continuous division and fusion. Damaged mitochondria are engulfed by lysosomes and degraded; this process was named mitophagy. Mitophagy provides an important guarantee for mitochondrial quality control. Thus, looking for solutions to heart disease from the perspective of mitophagy will be an important direction of future research for cardiomyopathy, including (but not limited to) searching for novel drugs or compounds that modulate the mitophagy process, exploring how drugs treat heart disease by affecting the mitophagy mechanism, and investigating how drug delivery can improve the treatment of heart disease.
This Special Issue on “Recent Advances in Modulating Mitophagy with Novel Drugs/Compounds” aims to provide up-to-date insights into the remarkable complexity of mitophagy and on its dysregulation in the context of many different kinds of heart diseases. We look forward to receiving your contributions.
Dr. Mingchong Yang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heart disease
- mitochondria
- mitophagy
- mitochondrial quality control
- drug screening
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
